# presbyopia FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/presbyopia

> No upcoming FDA catalysts in presbyopia; 4 past events are recorded.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA decisions for presbyopia?

No upcoming FDA catalysts in presbyopia; 4 past events are recorded. SEC Form 10-Q: "In February 2026, the FDA accepted the sNDA and set a Prescription Drug User Fee Act (PDUFA) action date of October 17, 2026." [Calendar and source filings](https://sec-api.dev/indications/presbyopia)

Source: SEC Form 10-Q, accession 0001628280-26-054381, https://www.sec.gov/Archives/edgar/data/1228627/000162828026054381/ird-20260630.htm (retrieved 2026-11-12). Last confirmed 2026-08-06. Cite: https://sec-api.dev/indications/presbyopia#answer

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| August 8, 2025 | [LNZ100 PDUFA date](https://sec-api.dev/pdufa/lnz100) | LENZ | presbyopia | completed, approved | "New Drug Application (NDA) for LNZ100 for treatment of presbyopia on track for PDUFA target action date of August 8, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1815776/000181577625000054/a991q225pressrelease.htm)) |
| February 23, 2026 | [MR-141 NDA/BLA acceptance](https://sec-api.dev/pdufa/mr-141) | VTRS | presbyopia | completed | "•In February 2026, the Company announced that the U.S. Food and Drug Administration (FDA) accepted for review the supplemental New Drug Application (sNDA) for MR-141 (phentolamine ophthalmic solution 0.75%) for the treatment of presbyopia." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1792044/000179204426000010/exhibit991-4q25earningsrel.htm)) |
| October 17, 2026 | [MR-141 PDUFA date](https://sec-api.dev/pdufa/mr-141) | VTRS | presbyopia | scheduled | "the FDA has assigned a PDUFA goal date of October 17, 2026 for MR-141 (phentolamine ophthalmic solution 0.75%) for the treatment of presbyopia" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1792044/000179204426000010/exhibit991-4q25earningsrel.htm)) |
| October 17, 2026 | [Opus Genetics, Inc. PDUFA date](https://sec-api.dev/companies/ird/catalysts) | IRD | presbyopia - | scheduled | "In February 2026, the FDA accepted the sNDA and set a Prescription Drug User Fee Act (PDUFA) action date of October 17, 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1228627/000162828026054381/ird-20260630.htm)) |

## Drugs

- [LNZ100](https://sec-api.dev/pdufa/lnz100) (LENZ)
- [MR-141](https://sec-api.dev/pdufa/mr-141) (VTRS)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/presbyopia.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "presbyopia FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/presbyopia

```bibtex
@misc{secapidev_indications_presbyopia_20261116,
  title        = {presbyopia FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/presbyopia}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_presbyopia_20261116","title":"presbyopia FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/presbyopia","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
